NCT Number: NCT00274560
A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol.
The objective of the study was to evaluate the degree of improvement in lung function in patients with chronic obstructive pulmonary disease (COPD) after treatment with tiotropium inhalation capsules compared to salmeterol inhalation aerosol .
Looking for future studies?
Notify MeKey information
Conditions
Age range
40 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 3
Primary location
HEMO Oy Health Center, Lahti, Finland
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Ability to sign a written Informed Consent Form consistent with International Conference of Harmonization-Good Clinical Practice (ICH-GCP) guidelines prior to participation in the trial (i.e., prior to any study procedures, including any pre-study washout of medications).
- Age of 40 years or older.
- Smoking history of ≥10 pack-years.
- A diagnosis of relatively stable chronic obstructive pulmonary disease with an Forced expiratory volume in one second (FEV1) ≤60% of predicted normal and FEV1 ≤70% of Forced vital capacity (FVC).
- Ability to perform technically acceptable pulmonary function tests, and ability to maintain records during the study period as required in the protocol.
- Ability to inhale medication from the HandiHaler® and from a metered dose inhaler.
Exclusion criteria
- Clinically significant diseases other than Chronic obstructive pulmonary disease (COPD). A clinically significant disease was defined as a disease or condition which, in the opinion of the investigator, could have put the patient at risk because of participation in the study or may have influenced either the results of the study or the patient's ability to participate in the study.
- Known moderate or severe renal insufficiency.
- A recent history (i.e., six months or less) of myocardial infarction.
- Unstable or life-threatening cardiac arrhythmias, including newly diagnosed, clinically relevant arrhythmia on the electrocardiogram (ECG) performed on Visit 1. Unstable arrhythmias included arrhythmias that required an intervention (i.e., hospitalization, cardioversion, pacemaker placement, and automatic implantable cardiac defibrillator (AICD) placement) or a change in drug therapy during the year preceding study enrollment.
- Hospitalization for heart failure during the past three years.
- History of life-threatening pulmonary obstruction, or a history of cystic fibrosis or clinically evident bronchiectasis.
- Other exclusion criteria apply.
Treatment and study plan
Salmeterol
DrugPrimary outcomes
-
FEV1 area under the curve for the time period of 0 to 12 hours (FEV1 AUC0-12)
Time frame: 12 weeks
-
peak FEV1
Time frame: 12 weeks
Secondary outcomes
-
Trough FEV1: Trough FEV1 was the FEV1 measured prior to dosing
Time frame: 12 weeks
-
Trough and peak FVC and FVC AUC0-12 measured at the same times as FEV1 on each test day
Time frame: 12 weeks
-
Individual FEV1 and FVC measurements at each timepoint
Time frame: 12 weeks
-
Number (%) of patients with at least one exacerbation of COPD
Time frame: 12 weeks
-
time to first exacerbation
Time frame: 12 weeks
-
number of exacerbations
Time frame: 12 weeks
-
number of exacerbation days
Time frame: 12 weeks
-
Average daily occasions of rescue medication [albuterol (salbutamol)] use each week
Time frame: 12 weeks
-
All adverse events
Time frame: 12 weeks
-
Pulse rate measured in conjunction with spirometry
Time frame: 12 weeks
-
Blood pressure (seated) measured in conjunction with spirometry
Time frame: 12 weeks
Sponsors and collaborators
Lead sponsor
Boehringer Ingelheim
Industry
Registry information
Official study title
A Multiple Dose Comparison of Tiotropium Inhalation Capsules and Salmeterol Inhalation Aerosol in a 12 Week, Randomized, Double-Blind, Double-Dummy Parallel Group Study in Patients With Chronic Obstructive Pulmonary Disease (COPD).
Important dates
- Study start
- 2002
- Primary completion
- 2003
- First posted
- Jan 11, 2006
- Registry last updated
- Dec 1, 2023
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder
NCT07252908
Chronic Disease, Disease Attributes
Chongqing, Chognqing, China
View Trial DetailsGenerative AI for Medication Counselling and Adherence in Community Pharmacies
NCT07649577
Asthma, Bronchial Diseases
Amman, Jordan
View Trial DetailsA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry
NCT06979518
Chronic Disease, Disease Attributes
Cypress, California, United States
View Trial DetailsDetecting Systemic Carbon Dioxide Levels With a Novel Biosensor
NCT06367686
Apnea, Chronic Disease
Tønsberg, Norway
View Trial Details